---
title: "\"Profit Warning\" BEISEN HOLDING's losses significantly reduced, with a maximum loss of 23.8 million RMB in the first half of the year"
description: "BEISEN HOLDING issued a profit warning, expecting a loss of between RMB 14.6 million and RMB 23.8 million for the six months ending in June, compared to a loss of RMB 99 million in the same period las"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262266122.md"
published_at: "2025-10-22T14:00:12.000Z"
---

# "Profit Warning" BEISEN HOLDING's losses significantly reduced, with a maximum loss of 23.8 million RMB in the first half of the year

> BEISEN HOLDING issued a profit warning, expecting a loss of between RMB 14.6 million and RMB 23.8 million for the six months ending in June, compared to a loss of RMB 99 million in the same period last year, a decrease of 76%-85%. This is mainly due to a reduction in share-based payments; and revenue is expected to increase by 15.2%-20.5%, reaching RMB 503 million to RMB 526 million

BEISEN HOLDING (09669.HK) issued a profit warning, expecting a loss of between RMB 14.6 million and RMB 23.8 million for the six months ending in June, compared to a loss of RMB 99 million in the same period last year, a decrease of 76%-85%. This is mainly due to a reduction in share-based payments; and revenue is expected to increase by 15.2%-20.5%, to between RMB 503 million and RMB 526 million

### Related Stocks

- [09669.HK - BEISEN HOLDING](https://longbridge.com/en/quote/09669.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hansoh Pharmaceutical Says Aumolertinib Mesylate Tablets Approved In EU As Monotherapy | Hansoh Pharmaceutical Group Company Ltd :AUMOLERTINIB MESYLATE TABLETS APPROVED IN EU AS MONOTHERAPY | [Link](https://longbridge.com/en/news/276401882.md) |
| Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as Monotherapy | Hansoh Pharmaceutical Group Company Limited announced that Aumolertinib Mesylate Tablets, known as Ameile in China, rece | [Link](https://longbridge.com/en/news/276480305.md) |
| Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | [Link](https://longbridge.com/en/news/276393466.md) |
| Berkshire Hathaway discloses investment in New York Times | Berkshire Hathaway has disclosed a new investment in the New York Times, reentering a sector it left in 2020. The compan | [Link](https://longbridge.com/en/news/276173033.md) |
| 04:38 ETAcceleronix e IDEMIA Secure Transactions lanzan el programa de acceso anticipado IFPP | Acceleronix and IDEMIA Secure Transactions have launched the IFPP Early Access Program at MWC26 Barcelona, in collaborat | [Link](https://longbridge.com/en/news/276429430.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.